

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68, C12N 5/00, G01N 33/543</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/36004</b>
			<b>(43) International Publication Date:</b> 2 October 1997 (02.10.97)
<b>(21) International Application Number:</b> PCT/NO97/00083 <b>(22) International Filing Date:</b> 25 March 1997 (25.03.97) <b>(30) Priority Data:</b> 961221 26 March 1996 (26.03.96) NO <b>(71)(72) Applicant and Inventor:</b> FODSTAD, Øystein [NO/NO]; Frits Kiærs vei 28, N-0383 Oslo (NO). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ENGEBRÅTEN, Olav [NO/NO]; Haneborgsveien 43A, N-1470 Lørenskog (NO). REE, Anne, Hansen [NO/NO]; Kirkeveien 87A, N-1344 Haslum (NO). HOVIG, Johannes, Eivind [NO/NO]; Sognsveien 31, N-0851 Oslo (NO). <b>(74) Agent:</b> ONSAGERS PATENTKONTOR A/S; P.O. Box 265 Sentrum, N-0103 Oslo (NO).			<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> IMMUNO-MAGNETIC CELL SEPARATION USED IN IDENTIFICATION OF GENES ASSOCIATED WITH SITE-PREFERRED CANCER METHASTASIS FORMATION			
<b>(57) Abstract</b>  Method for identifying genes with site specific or site preferred expression in target cells that are initially detected and isolated by repeated immuno-magnetic procedures. The purified target cells are then exposed to known cloning procedures. Preferred target cells are malignant cells, e.g. metastatic cells. Gene cloning methods may include the differential display or subtractive hybridization approaches.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Immuno-Magnetic cell separation used in identification of genes associated with site-preferenced cancer methastasis formation.

5 The object of the present invention is to provide a novel approach for detecting new genes with site-specific expression patterns in tumor cells residing in different tissues.

10 It is well known that many cancer types show typical patterns of spread, in that metastases appear preferably in certain tissues or organs, often in an orderly fashion. Thus, breast cancer metastases usually first develop in axillary lymph nodes, whereas bone marrow/bone metastases represent the first and most common (50%) site of distant spread. Of other tissues, liver, lung and the central nervous system (up to 20%) become hosts of breast cancer metastases. Similarly, prostate cancer gives skeletal metastases; colon cancer spreads to lymph nodes and liver; 15 osteosarcoma to lung; and malignant melanoma to lymph nodes, liver, lung and brain. Very little is known about the factors that determine such tissue-preferenced cancer spread, but specific characteristics of the tumor cells are certainly involved, by e.g. enabling the tumor cells to home in the target organ, move to and invade the host tissue, respond to local growth factors, induce angiogenesis, or react in 20 hitherto unknown ways. These characteristics must be associated with expression of specific proteins expressed by known or unknown genes. To identify such genes may, therefore, be of great importance in the understanding of the mechanisms of metastasis and thereby provide new leads or clues for diagnosis and therapy.

25 Several methods are being used in the search for genes that are highly expressed in certain populations of cells and not in other, including procedures such as subtractive hybridization cloning and the use of the differential display approach. Most such cloning projects have involved the use of *in vitro* cell lines or clones as starting material. However, it is known that cell lines may differ significantly from 30 the tumor cells from which they originated, and that *in vitro* culture conditions may up- or down-regulate the expression of genes involved in deciding the ability of the cells to invade extracellular matrices and stromal tissue as well as their overall metastatic capacity.

35 A logical alternative to cell lines for comparing the expression of gene transcripts or proteins of interest would be to use specimens of tumor tissue from primary tumors and metastases from patients. Such an approach does, however, include several possibilities for error and also technical difficulties. When using tumor cells from different patients the expression of genes characteristic of each

individual must be subtracted before the patterns of gene expression related to the objective of the study are compared. This adds to the immense complexity of such gene cloning. It would be advantageous, therefore, to be able to compare expression patterns in cancer cells obtained from tumor manifestations located at different sites in one and the same individual. This may be possible by collecting tumor tissue from both the primary tumor and overt metastases detected and removed at surgery, and/or by surgery or biopsy of recurrent disease, or from secondary tumors in patients with progressive disease who have or have not received other treatment modalities after primary surgery.

In any gene cloning project it is important to work with as pure populations of target cells as possible, attempting to avoid irrelevant signals from non-target cells blurring the expression patterns to be compared. In specimens from solid tumors this is difficult to achieve, as in surgical specimens and biopsies the tumor cells will be mixed with normal fibrous tissue, including stromal and endothelial cells, that conventional methods of tissue preparation cannot satisfactorily remove. In hematological cancers, the malignant cells share determinants of a corresponding subpopulation of normal cells, preventing separation of the two types of cells.

In attempts to identify genes that are involved in the early stages of tumor dissemination, it would be important to obtain tumor cells from the relevant sites when the size of the secondary tumors is small, or if possible even from subclinical tumor foci or cells. One example would be malignant cells present in blood or in bone marrow before conventional diagnostic measures can demonstrate solid manifestation of metastasis. Another example would be cancer cells present in cerebrospinal fluid, in urine, or in effusions in pleural and abdominal cavities before conventional morphological procedures can detect such cells. Moreover, at primary surgery or if suspected for metastatic spread, lymph nodes are often removed because they are enlarged. Morphological examination may, however, still be negative in cases where a limited number of tumor cells still might be present. In all these examples the present invention describes a means of detecting and selecting the target tumor cells for gene cloning purposes.

In addition to using cancer cells obtained from different tissues or organs in patients, the invention also describes another way of obtaining metastatic human tumor cells for use in the search for genes with site-specific expression. Cells from several human tumors have been grown *in vitro* or in immunodeficient animals *in vivo*, and such cells have been used to establish experimental metastasis models or models in which the cells can be grown orthotopically, i.e. in the clinically relevant

tissues of origin; malignant melanoma in the skin; osteosarcoma in bone; colorectal cancer in the bowel wall; breast cancer in the mammary fat pad, etc. In experimental metastasis models different patterns of tumor spread can be seen, depending on the cell line, the route of cell injection, and the type of host used.

5 Commonly the metastasis patterns simulate that of the corresponding tumor type in the clinic. By using such models it becomes possible also to obtain tumor cells from metastatic sites not usually accessible in patients, such as the spinal cord and the brain tissue. Again, for gene cloning purposes it would be important to select the human tumor cells from the animal cells to avoid problems with genes  
10 expressed in the normal host cells.

Previously it has been impossible to perform meaningful gene cloning experiments on specimens of solid tumors and metastases and on malignant cells in blood and bone marrow with the object of identifying genes with site-specific expression.

15 This is because a considerable fraction of solid tumors and metastases is not malignant cells but connective tissue supporting and growing in between the malignant cells, and which also contains blood vessels that provide the necessary supply of nutritional factors and oxygen to the tumor. It has not been regarded as possible to adequately separate tumor cells from the normal cells without including  
20 an intermediate step of culturing the cells *in vitro*, involving manipulations to get rid of the normal cells. However, such *in vitro* cultivation would result in a selection of subpopulation of tumor cells in an environment quite different from the situation *in vivo*, thereby inducing significant changes in gene expression patterns. Therefore, for the purpose of identifying genes associated with the  
25 metastatic process, cultivation of tumor cells from solid metastases cannot be used. Moreover, it has not been regarded of interest to persons known in the field of gene cloning to compare gene expression patterns in malignant cells in untreated solid primary and metastatic tumors. Furthermore, in samples of blood and bone marrow tumor cells, if at all present, constitute a very low fraction of the total number of  
30 nucleated cells, and the malignant cells in blood and bone marrow have not been regarded of interest for gene cloning attempts. This is because the tumor cells could not be adequately separated from normal cells, and importantly also because people known in the art of gene cloning have not expected that such malignant cells were sufficiently different in gene expression patterns from those in the  
35 parent tumors.

Cancer cells isolated from human tumors metastasizing to different and clinically relevant target tissues and organs in immunodeficient animals have not been used in attempts to identify tumor-associated genes with site-specific expression, simply

because such human tumor models are very rare, but importantly also because of the lack of methods to obtain pure populations of cancer cells.

5 The object of the present invention is therefore to provide a method by which target cells can be separated from a cell population in order to identify the gene sequences from the target cells in a specific cell population environment.

This object has been obtained by the present invention characterized by the enclosed claims.

10 Since the object of the invention is to identify genes expressed specifically during early stages of tumor dissimulation, the solid tumors and metastases should be small in size, and the malignant cells in blood and bone marrow should represent so-called micrometastatic disease, i.e. a limited a number of tumor cells should be  
15 present. If possible, such tumor cells should be collected even in cases where said cells cannot be detected by conventional morphological examinations or with diagnostic procedures such as radiology and magnetic resonance imaging. Evidently, since such cells have not been recognizable they have not been of interest for gene cloning purposes. The use of immunomagnetic techniques permits  
20 isolation of said malignant cells even when present in low numbers. Various methods for amplifying DNA and RNA sequences make gene cloning possible on such low numbers of malignant cells, provided that this cell population is sufficiently pure.

25 The positive selection of target tumor cells can be obtained by the use of per se known techniques, as described in patent application PCT/NO93/00136 (WO 94/07139) and in PCT/NO95/00052. Since in the present case the purity of the final target cell population is important, the immunomagnetic selection process may be performed more than once, or may be performed as a combination of  
30 positive (with target-cell recognizing monoclonal antibodies) and negative (with antibodies that bind to unwanted cells) selection. These techniques have been successfully used to isolate target cells from blood, bone marrow, malignant effusions, and from single cell suspensions prepared from solid tumor tissue of primary tumors and lymph node and other metastases. Similarly, the selection of  
35 human malignant cells from normal stromal or hematopoietic cells in animal hosts has also been demonstrated, even in cases where the tumor cells resided in bone, bone marrow, the spinal cord or in brain tissue. Since one objective would be to search for genes with products involved in the early stages of metastasis formation it may happen that only relatively few tumor cells can be obtained, the purity of

which is particularly important. With this approach it is possible to obtain a better purified target cell population from patients and animal hosts than by any other known technique, providing unique possibilities for cloning genes with site-specific expression.

5

The next step of the invention involves the use of known gene cloning procedures, such as the use of the differential display procedure first described by Liang, A. and Pardee, A.B. (Science, Vol 257, 967-971, 1992). In this method, polymerase chain reactions are performed with enzymes and primers that give reverse transcription and random amplification of gene transcripts present in the target cells. Resulting cDNA fragments from the cell populations to be compared are thereafter studied on a sequencing gel and the site-specific fragments extracted and sequenced. Gene fragments of interest can then be further studied, including examination of their expression patterns in material similar to that used for cloning. Again, having access to purified tumor cell populations without irrelevant non-target cells interfering with the results is very important. The possibility of using human tumor cells isolated from metastasis models in immunodeficient animals is advantageous also because the models provide a reliable and continuous source of target tumor cells for extended studies. It is also important that the target cells, either from patients or from animal models, are isolated and treated for DNA and RNA studies directly and very rapidly to avoid unwanted alterations in gene expression not related to the objective of identifying genes with site-specific expression.

10

15

20

25

30

Different methods used for cloning new genes have their inherent limitations. The differential display-methods based on polymerase chain reaction techniques may suffer from problems related to representativity and reproducibility. With our approach we have consequently included steps aimed at minimizing such problems. This has been achieved mainly by the use of the immunobead selection technique which makes it possible to study specifically biologically representative cells, not only for the first differential display step, but also in the steps where the candidate genes are examined for expression levels in relevant cells and tissues.

35

#### Example 1:

Tumor cells from the primary tumor and axillary lymph nodes from a breast cancer patient were prepared by physical and enzymatic methods to obtain a single cell suspension. A bone marrow sample (50 ml) was aspirated and a peripheral blood sample was obtained by venous puncture, and the mononuclear cells from both

occasions were isolated on Lymphoprep (Nycomed Pharma, Oslo, Norway). The cell suspensions were independently incubated with the MOC-31 and BM7 monoclonal antibodies, recognizing a pan-epithelial antigen and the MUC-1 gene product, respectively. After washing and incubation Dynabeads M-450 SAM SD (Dyna, Oslo, Norway), which bind to the Fc-region of the primary antibodies, were added. Tumor cells with bound antibody-Dynabeads M-450 SAM SD complex could thereafter be isolated from the normal mononuclear cells by the use of a strong magnet. The nature of the selected cells was confirmed microscopically. From the different cell populations RNA was extracted and the material subjected to the differential display cloning procedure (Liang and Pardee, 1992), in which partial cDNA-sequences from mRNA subpopulations obtained by reverse transcription were amplified by polymerase chain reaction. Comparison of cDNA-fragments from the various tumor cell populations were compared on a sequencing gel, and fragments specifically expressed in cells obtained from one of the sites were extracted and sequenced. Among a number of interesting gene sequences with specific expression either in tumor cells isolated, with our magnetic immunobead technology, from bone marrow or in tumor cells immunomagnetically isolated from lymph node metastases, we have found one cell cycle related transcription factor, one oncogene product, in addition to genes not yet identified. The expression of the two identified gene sequences in biologically relevant model systems and clinical material is presently being analyzed.

#### Example 2:

In this example, cells from a model for experimental metastasis of a human breast cancer were used. In athymic, nude rats injection of MA-11 human breast cancer cells into the cisterna magna (CM) results in leptomeningeal spread and growth of the malignant cells. Moreover, MA-11 cells injected into the left cardiac ventricle (LV) form metastases in the spinal cord which result in the development of hind leg paralysis in the animals after approximately 35 days. Tumor cells from both locations were obtained by mincing the host tissue and preparing single cell suspensions, and the immunobead technique described under example 1 was used to positively select the malignant cells. Thereafter, RNA extraction of cells from the two sites, together with *in vitro* cultured MA-11 cells was performed and the material similarly subjected to the differential display cloning procedure as already described. In addition, mRNA extracted from relevant normal tissues in the rats were included as controls. It should be noted that the MA-11 cell line was established from micrometastatic tumor cells isolates with the immunomagnetic method from the bone marrow of a stage II breast cancer patient. Several candidate fragments specific for the cells growing in the leptomeninges or as metastases to



the spinal cord have been detected. Sequence analysis showed that these fragments represent both novel and known genes. Among the fragments confirmed as differentially expressed in MA-11 cells selected from metastatic cell, four candidate genes have so far been examined in more detail. Two of these, termed LV1 and LV12 are particularly interesting. LV1 shows very high expression selectivity in tumor cells from spinal cord metastases, whereas LV12 is downregulated in leptomeningeally growing cells. LV1 is found to be upregulated in a number of cell lines known to have a high capacity to form experimental metastasis in immunodeficient animals. In a panel of primary tumours from breast cancer patients, low expression of LV12 was related to short survival of the corresponding patients. Altogether the results show that LV1 mRNA seems to be upregulated in highly metastatic cells, and LV12 mRNA level was inversely correlated to progression and metastasis of breast cancer cells. Both genes are novel. In addition, a third promising candidate gene, CM13, is also a novel gene upregulated in tumor cells growing in the leptomeninges. Several other candidates are still to be further analyzed. For both LV1 and LV12 cDNA full length cloning has been initiated.

#### Example 3:

In a similar model to that described in example 2, MT1 human mammary cancer cells give rise to growth in the leptomeninges after CM injection, whereas LV injected cells metastasize to the bone marrow and bone in the vertebra of the spine and in the long bones. Cells from these two locations as well as *in vitro* grown cells have been isolated and RNA from the different cell populations has been extracted. Similar cloning procedures to those described in example 2 can be applied to this material.

#### Example 4:

Tumor cells isolated by the technique described in example 1 have been isolated from other breast cancer patients, from patients with colorectal cancers where the tumor cells were isolated from primary and recurrent tumors, from lymph nodes and liver metastasis, and blood and bone marrow samples, and from prostate cancer patients with cells selected from primary or recurrent tumor specimens, from lymph nodes in addition to specimens from blood and bone marrow. The isolated cells can be used for gene cloning purposes.

In addition to the use of the material described in examples 1-4 for gene cloning, it can be used for examining the expression patterns of all gene sequences of sufficient promise.

## PATENT CLAIMS

1. Method for identifying genes with site-specific or site preferred expression in specific target cells present in a cell environment different or not from that of their origin,

5 **characterized in** that the target cells initially are detected and isolated by repeated immuno-magnetic procedures in order to obtain up to 100% specific target cells before exposing the said target cells to known cell cloning procedures.

2. Method according to claim 1,

10 **characterized in** that the used target cells are malignant cells obtained from solid primary or recurrent tumors; and/or from metastases from such tumors to lymph nodes; and/or blood; and/or bone marrow; and/or bone tissue; and/or liver; and/or lungs; and/or central nervous system; and/or malignant pleural effusions and ascites, urine; and/or cerebral spinal fluid; and/or other organ sites.

15 3. Method according to claims 1-2,

**characterized in** that the malignant cells are isolated from single cell suspensions prepared from solid tumor manifestations; and/or from mononuclear cell fractions obtained from bone marrow or blood samples; and/or from cells present in other  
20 body fluids.

4. Method according to claims 1-2,

**characterized in** that the malignant cells used are *in vitro* cultivated human tumor cells; and/or human tumor cells grown in specific tissues in immunodeficient  
25 animals; and/or experimental human tumor metastases in such animals.

5. Method according to claims 1-4,

**characterized in** that RNA and/or DNA are extracted from the isolated cells.

30 6. Method according to claim 5,

**characterized in** that the extracted nucleic acids are used for gene cloning purposes.

7. Method according to the above claims,

35 **characterized in** that the said gene cloning method is the differential display or the subtractive hybridization approaches, or any other procedure that can be used to identify genes with differential expression.

8. Method according to claim 7,  
**characterized in** that amplified cDNAs obtained from malignant cells selected  
from different sites are studied and compared on sequencing gels, and where those  
with interesting site-specific or site-preferenced patterns are sequenced and  
5 identified.

9. Method according to claim 8,  
**characterized in** that the expression patterns of identified gene sequences are  
studied on material obtained from all relevant tumor cell sites described in claims  
10 1-4.

10. Method according to the preceding claims,  
**characterized in** that previously unknown genes identified in preceding claims are  
used for gene therapy purposes, and/or as targets for procedures aimed at altering  
15 or inactivating the genes or their products.

11. Use of the method according to claim 1, to obtain specific gene sequences  
and their expression products in target cells present in cell environments different  
or not from their origin.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/NO 97/00083

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC6: C12Q 1/68, C12N 5/00, G01N 33/543 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A61K, C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CANCERLIT, EMBASE, WPI		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9524648 A1 (FODSTAD), 14 Sept 1995 (14.09.95), page 4, line 2 - page 8, line 9  --	1-9
X	WO 9407139 A1 (FODSTAD), 31 March 1994 (31.03.94), See pages 4-8 and 16 and claim 14  --	1-9
X	National Library of Medicine, file Medline, Medline accession no. 95268055, Van Epps DE et al: "Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood", Blood Cells 1994;20(2-3):411-23  --	1-6
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
1 July 1997		08 -07- 1997
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  Carl-Olof Gustafsson Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/NO 97/00083

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Dialog Information Service, file 154, Medline, Dialog accession no. 07911215, Medline accession no. 94231000, Wixler V. et al: "Isolation and quantification of class I MHC gene mutants in mouse T cells by immunoselection with a magnetic cell sorter (MACS)", J Immunol Methods May 2 1994, 171 (1) p121-30  --	1,5,6
X	Dialog Information Service, file 154, Medline, Dialog accession no. 06887713, Medline accession no. 92084142, Kappes DJ et al: "A novel method for generating stable high-level transfectants involving direct immunomagnetic selection for cell-surface epitopes: expression of HLA class-II genes in HeLa cells", Gene Dec 15 1991, 108 (2) 245-52  --	1,4-6
X	Dialog Information Service, file 159, Cancerlit, Dialog accession no. 01195522, Cancerlit accession no. 96133084, Yaremko ML et al: "Immunomagnetic separation can enrich fixed solid tumors for epithelial cells", Am J Pathol; 148(1):95-104 1996  --	1-3,5,7
X	National Library of Medicine, file Medline, Medline accession no. 95325659, Griwatz C et al: "An immunological enrichment method for epithelial cells from peripheral blood", J Immunol Methods 1995 Jun 28;183(2):251-65  --	1-9
P,X	Dialog Information Service, file 159, Cancerlit, Dialog accession no. 01193425, Cancerlit accession no. 96709393, Ree AH et al: "Identification of site specific gene expression in metastatic breast cancer cells (Meeting abstract)", Proc Annu Meet Am Assoc Cancer Res; 37:A607 1996  --	1-9

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/NO 97/00083

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>Dialog Information Service, file 159, Cancerlit,  Dialog accession no. 01192976, Cancerlit accession  no. 96653514, Brandt B. et al: "Isolation of single  cancer cells and coherent cell sheets from  peripheral blood of cancer patients with reference  to shed cytokeratin 8/18 and erbB-2 oncoprotein  fragments (Meeting abstract)", Proc Annu Meet Am  Assoc Cancer Res; 37:A555 1996</p> <p style="text-align: center;">--</p>	1-9
A	<p>Dialog Information Service, file 159, Cancerlit,  Dialog accession no. 00864158, Cancerlit accession  no. 92257480, Gazitt Y et al: "Expression of N-Myc,  and MDR-1 Proteins in Newly Established Neuro-  blastoma Cell Lines: A Study by Immunofluorescence  Staining and Flow Cytometry",  Cancer Res; 52(10):2957-65 1992</p> <p style="text-align: center;">--  -----</p>	1-9

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/NO 97/00083

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9524648	A1	14/09/95	AU	2086495 A	25/09/95
				CA	2185128 A	14/09/95
				EP	0749580 A	27/12/96
				FI	963533 A	07/11/96
				NO	180658 B	10/02/97
				NO	940866 A	11/09/95
				PL	316209 A	23/12/96
-----						
WO	9407139	A1	31/03/94	AU	2593192 A	12/04/94
				AU	4836393 A	12/04/94
				CA	2144328 A	31/03/94
				EP	0660930 A	05/07/95
				FI	951161 A	09/05/95
				HU	73741 A	30/09/96
				HU	9500723 D	00/00/00
				JP	8501390 T	13/02/96
				NO	950918 A	10/05/95
				PL	308109 A	24/07/95
				SK	32995 A	11/10/95
				WO	9407138 A	31/03/94
-----						